Clinical Trial Update: Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) [Phase 1]

View source ↗

Summary

A Phase 1 safety study of intravitreal POT-4 therapy for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• POT-4

Snippet

Sponsor: Potentia Pharmaceuticals, Inc. | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED